MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wang, Bao Wei ^a,b   Wu, Gong Jhe ^b,c   Cheng, Wen Ping ^b   Shyu, Kou Gi ^b,d  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMODYNAMICS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; MYOCARDIUM; ORGAN SIZE; RATS;

EID: 84894252009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084188     Document Type: Article

References (33)

1. Sutton MGSJ, Sharpe N (2000) Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation 101:2981-2988.
2. Fonsatti E, Altomonte M, Arslan P, Maio M (2003) Endoglin (CD105): a target for anti-angiogenic cancer therapy. Curr Drug Targets 4:291-296. (Pubitemid 36443247)
3. Chen K, Mehta JL, Li D, Joseph L, Joseph J (2004) Transforming growth factor-β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 95:1167-1173. (Pubitemid 39648207)
4. Rodríguez-Barbero A, Obreo J, Alvarez-Munoz P, Pandiella A, Bernabéu C, et al. (2006) Endoglin modulation of TGF-β1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem 18:135-142.
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
6. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105:1608-1613. (Pubitemid 351346562)
7. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, et al. (2007) Altered microRNA expression in human heart disease. Physiol. Genomics 31:367-373 (Pubitemid 350127777)
8. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M (2007) MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100: 416-424.
9. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN (2007) Control of stress dependent cardiac growth and gene expression by a microRNA. Science 316:575-579. (Pubitemid 46683138)
10. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, et al. (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772-2786.
11. Shyu KG, Wang BW, Wu GJ, Lin CM, Chang H (2013) Mechanical stretch via transforming growth factor-β1 activates microRNA208a to regulate endoglin expression in cultured rat cardiac myoblasts. Eur J Heart Fail 15:36-45.
12. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, et al. (2012) Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation 125:2728-2738.
13. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, et al. (2005) Carvedilol modulates the expression of hypoxia-inducible factor-1α and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail 11:156-165.
14. Shyu KG, Ko WS, Yang WS, Wang BW, Kuan P (2005) Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 68:405-14.
15. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108. (Pubitemid 351818697)
16. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR (2010) Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 12:219-226.
17. Kapur NK, Heffernan KS, Yunis AA, Parpos P, Kiernan MS, et al. (2010) Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol 106:1770-1776.
18. Yanavitski M, Givertz MM (2011) Novel biomarkers in acute heart failure. Curr Heart Fail Rep 8:206-211.
19. Benjamin IJ (2012) Targeting endoglin, an auxiliary transforming growth factor-β coreceptor, to prevent fibrosis and heart failure. Circulation 125:2689-2691.
20. Cheng Y, Ji R, Yue J, Yang J, Liu X, et al. (2007) MicroRNAs are aberrantly expressed in hypertrophic heart. Do they play a role in cardiac hypertrophy? Am J Pathol 170:1831-1839.
21. Wang BW, Wu GJ, Cheng WP, Shyu KG (2013) Mechanical stretch via transforming growth factor-β1 activates microRNA-208a to regulate hypertrophy in cultured rat cardiac myocytes. J Formo Med Assoc 112;635-643.
22. Broberg CS, Chung SS, Conklin C, Jerosch-Herold M (2010) Quantitation of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging 3:727-734.
23. Lambert V, Capderou A, Le Bret E, Rucker-Martin C, Deroubaix E, et al. (2010) Right ventricular failure secondary to chronic overload in congenital heart disease: an experimental model for therapeutic innovation. J Thorac Cardiovasc Surg 139:1197-1204.
24. Horwich TB, MacLellan R, Fonarow GC (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43:642-648. (Pubitemid 38229538)
25. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, et al. (2007) Effect of high-dose atorvastatin on hospitalization for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 115:576-583. (Pubitemid 46226167)
26. Pospisilova N, Semeeky V, Jamborova G, Pospechova K, Solichova D, et al. (2006) Endoglin expression in hypercholesterolemia and after atorvastatin treatment in apo-E deficient mice. J Pharm Pharmaceut Sci 9:388-397. (Pubitemid 46630113)
27. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, et al. (2007) Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol 85:767-773. (Pubitemid 350144736)
28. Chen J, Mehta J (2006) Angiotensin II-mediated oxidative stress and procollagen-I expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291: H1738-H1745. (Pubitemid 44497679)
29. Brown JH, Del Re DP, Sussman MA (2006) The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98:730-742.
30. Kurata T, Miyazaki K, Kozuki M, Panin V, Morimoto N, et al. (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371:161-170.
31. Landmesser U, Engberding N, Bahilman FH, Schaefer A, Wiencke A, et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110:1933-1939. (Pubitemid 39331904)
32. Chiu CZ, Wang BW, Shyu KG (2012) Atorvastatin, valsartan, and N-acetylcysteine prevent cardiac hypertrophy and overexpression of myocardin in pressure-overloaded rat heart. Acta Cardiol Sin 28:286-296.
33. Dubey G, Sharma PL, Sharma S (2013) Possible involvement of "Phosphatidylinositol-3-kinase and endothelial nitric oxide synthase" in experimental obesity induced vascular endothelial dysfunction. J Applied Pharmaceutical Sci 3:52-60.